Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912519967> ?p ?o ?g. }
- W2912519967 endingPage "101131" @default.
- W2912519967 startingPage "101131" @default.
- W2912519967 abstract "Chemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of cytoprotective genes. Nrf2 not only plays a critical role in chemoprevention, but also contributes to chemoresistance. In this study, we found that digoxin markedly reversed drug resistance of gemcitabine by inhibiting Nrf2 signaling in SW1990/Gem and Panc-1/Gem cells. Further research revealed that digoxin regulated Nrf2 at transcriptional level. In in vivo study, we found that digoxin and gemcitabine in combination inhibited tumor growth more substantially when compared with gemcitabine treatment alone in SW1990/Gem-shControl cells-derived xenografts. In the meantime, SW1990/Gem-shNrf2 cells-derived xenografts responded to gemcitabine and combination treatment similarly, suggesting that digoxin sensitized gemcitabine-resistant human pancreatic cancer to gemcitabine, which was Nrf2 dependent. These results demonstrated that digoxin might be used as a promising adjuvant sensitizer to reverse chemoresistance of gemcitabine-resistant pancreatic cancer to gemcitabine via inhibiting Nrf2 signaling." @default.
- W2912519967 created "2019-02-21" @default.
- W2912519967 creator A5011515414 @default.
- W2912519967 creator A5019452654 @default.
- W2912519967 creator A5031093155 @default.
- W2912519967 creator A5035662159 @default.
- W2912519967 creator A5050909388 @default.
- W2912519967 creator A5054070832 @default.
- W2912519967 creator A5055384975 @default.
- W2912519967 creator A5070812231 @default.
- W2912519967 creator A5074642572 @default.
- W2912519967 creator A5088499165 @default.
- W2912519967 date "2019-04-01" @default.
- W2912519967 modified "2023-10-14" @default.
- W2912519967 title "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway" @default.
- W2912519967 cites W1514403557 @default.
- W2912519967 cites W1591240009 @default.
- W2912519967 cites W1755092205 @default.
- W2912519967 cites W1967108243 @default.
- W2912519967 cites W1967231442 @default.
- W2912519967 cites W1971090593 @default.
- W2912519967 cites W1975812656 @default.
- W2912519967 cites W1985599649 @default.
- W2912519967 cites W1995589159 @default.
- W2912519967 cites W1996521867 @default.
- W2912519967 cites W2001399513 @default.
- W2912519967 cites W2001649834 @default.
- W2912519967 cites W2003962390 @default.
- W2912519967 cites W2024728867 @default.
- W2912519967 cites W2031034208 @default.
- W2912519967 cites W2032627423 @default.
- W2912519967 cites W2040114786 @default.
- W2912519967 cites W2045246542 @default.
- W2912519967 cites W2051853815 @default.
- W2912519967 cites W2053350368 @default.
- W2912519967 cites W2053671318 @default.
- W2912519967 cites W2055904567 @default.
- W2912519967 cites W2056344573 @default.
- W2912519967 cites W2057721542 @default.
- W2912519967 cites W2060241324 @default.
- W2912519967 cites W2065498165 @default.
- W2912519967 cites W2068878269 @default.
- W2912519967 cites W2077950988 @default.
- W2912519967 cites W2078690146 @default.
- W2912519967 cites W2079596789 @default.
- W2912519967 cites W2084644507 @default.
- W2912519967 cites W2086140220 @default.
- W2912519967 cites W2104718696 @default.
- W2912519967 cites W2105599787 @default.
- W2912519967 cites W2108417479 @default.
- W2912519967 cites W2112474929 @default.
- W2912519967 cites W2113024198 @default.
- W2912519967 cites W2123350401 @default.
- W2912519967 cites W2125837657 @default.
- W2912519967 cites W2129799427 @default.
- W2912519967 cites W2132057867 @default.
- W2912519967 cites W2132336832 @default.
- W2912519967 cites W2133709950 @default.
- W2912519967 cites W2133954905 @default.
- W2912519967 cites W2135664375 @default.
- W2912519967 cites W2154460302 @default.
- W2912519967 cites W2156060653 @default.
- W2912519967 cites W2166825884 @default.
- W2912519967 cites W2170619905 @default.
- W2912519967 cites W2206843293 @default.
- W2912519967 cites W2235523093 @default.
- W2912519967 cites W2264784358 @default.
- W2912519967 cites W2471144200 @default.
- W2912519967 cites W2493380788 @default.
- W2912519967 cites W2515257966 @default.
- W2912519967 cites W2550182409 @default.
- W2912519967 cites W2564083928 @default.
- W2912519967 cites W2592895660 @default.
- W2912519967 cites W2616410411 @default.
- W2912519967 cites W2766275958 @default.
- W2912519967 cites W2986701595 @default.
- W2912519967 doi "https://doi.org/10.1016/j.redox.2019.101131" @default.
- W2912519967 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6365940" @default.
- W2912519967 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30735911" @default.
- W2912519967 hasPublicationYear "2019" @default.
- W2912519967 type Work @default.
- W2912519967 sameAs 2912519967 @default.
- W2912519967 citedByCount "36" @default.
- W2912519967 countsByYear W29125199672019 @default.
- W2912519967 countsByYear W29125199672020 @default.
- W2912519967 countsByYear W29125199672021 @default.
- W2912519967 countsByYear W29125199672022 @default.
- W2912519967 countsByYear W29125199672023 @default.
- W2912519967 crossrefType "journal-article" @default.
- W2912519967 hasAuthorship W2912519967A5011515414 @default.
- W2912519967 hasAuthorship W2912519967A5019452654 @default.
- W2912519967 hasAuthorship W2912519967A5031093155 @default.
- W2912519967 hasAuthorship W2912519967A5035662159 @default.
- W2912519967 hasAuthorship W2912519967A5050909388 @default.
- W2912519967 hasAuthorship W2912519967A5054070832 @default.
- W2912519967 hasAuthorship W2912519967A5055384975 @default.
- W2912519967 hasAuthorship W2912519967A5070812231 @default.
- W2912519967 hasAuthorship W2912519967A5074642572 @default.